G1 Therapeutics has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of Cosela (trilaciclib), a pioneering treatment designed to reduce bone marrow suppression caused by chemotherapy in adults. This approval marks a critical advancement in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Details of Cosela’s Impact and […]
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma, a rare and aggressive cancer. FDA’s Recognition Enhances Clinical Development The FDA’s […]
Sandoz, a division of the Swiss pharmaceutical giant Novartis, has finalized a deal to acquire the cephalosporin antibiotics business from GSK (GlaxoSmithKline) for up to $500 million. This acquisition grants Sandoz global rights to three major antibiotic brands: Zinnat, Zinacef, and Fortum in over 100 markets, significantly enhancing its position in the antibiotics market. Exclusions […]
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF). This marks a significant step forward in the treatment options available […]
DJO, a leading provider of medical technologies based in Texas, has strategically enhanced its presence in the foot and ankle surgery market with the acquisition of Trilliant Surgical, a prominent provider of orthopedic foot and ankle implants. The acquisition, completed in January 2021 for an undisclosed sum, marks another significant step in DJO’s expansion following […]
US pharmaceutical giant Pfizer has withdrawn its application for emergency use authorization of its BNT162b2 COVID-19 vaccine in India. This decision comes after a series of interactions with the Indian drug regulator, which had requested additional information regarding the vaccine. Regulatory Hurdles and Safety Concerns Initially submitted for approval in December 2020, the application faced […]
Thermo Fisher Scientific has entered into a significant agreement with Chinese cell therapy leader JW Therapeutics, granting non-exclusive commercial access to its Gibco CTS Dynabeads CD3/CD28 technology. This collaboration is set to accelerate the clinical development and commercial manufacturing of CAR-T therapies in China, focusing on JW Therapeutics’ pioneering product, relmacabtagene autoleucel (relma-cel). Enhancing CAR-T […]
VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS clinical trial. This trial will evaluate the efficacy and safety of apraglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog, in treating patients with Short Bowel Syndrome (SBS) with intestinal failure (SBS-IF). The STARS trial marks the largest phase […]
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to acquire British-based GW Pharmaceuticals in a monumental $7.2 billion cash-and-stock transaction. This acquisition is set to create a powerhouse in the neuroscience field with a robust global commercial and operational footprint. Strategic Acquisition to Enhance Neuroscience Portfolio […]
Bexson Biomedical has raised $4.8 million in a Series A financing round for developing a subcutaneous ketamine treatment platform for pain management and mental health disorders. The Series A round was led by Noetic Psychedelic Fund. Michael Franks – a Managing Partner at Noetic Psychedelic Fund said: “We are very excited to support the entire […]